Skip to content

Annexon ANNX Stock-Based Comp

Stock-Based Comp at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$257.4M+0.7%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$10.6M+99.5%
Omeros logo
OmerosOMER
$1.89M-23.0%
Vor Biopharma logo
Vor BiopharmaVOR
$8.87M+359%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$7.62M-18.8%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$3.36M-13.9%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's stock-based comp?
Annexon (ANNX) reported stock-based comp of $4.16M in Q1 2026.
How has Annexon's stock-based comp changed year-over-year?
Annexon's stock-based comp decreased by 18.2% year-over-year, from $5.08M to $4.16M.
What is the long-term trend for Annexon's stock-based comp?
Over 4 years (2021 to 2025), Annexon's stock-based comp has grown at a 0.2% compound annual growth rate (CAGR), from $16.26M to $16.42M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.